SARS-CoV-2 and Systemic Lupus Erythematosus

被引:0
作者
Aikaterini Thanou
Amr H. Sawalha
机构
[1] Oklahoma Medical Research Foundation,Arthritis and Clinical Rheumatology Program
[2] University of Pittsburgh School of Medicine,Departments of Pediatrics, Medicine, and Immunology, and Lupus Center of Excellence
来源
Current Rheumatology Reports | 2021年 / 23卷
关键词
Systemic lupus erythematosus; COVID-19; Immunosuppression;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 540 条
[1]  
Kaul A(2016)Systemic lupus erythematosus Na Rev Dis Primers 2 16039-1294
[2]  
Gordon C(2020)COVID-19: immunology and treatment options Clin Immunol 215 108448-941
[3]  
Crow MK(2013)Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies Lupus. 22 1286-ee5
[4]  
Touma Z(2020)Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study BMJ. 369 m1966-206
[5]  
Urowitz MB(2020)Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study BMJ. 369 m1985-1063
[6]  
van Vollenhoven R(2020)Immunology of COVID-19: current state of the science Immunity. 52 910-474
[7]  
Ruiz-Irastorza G(2020)The renin-angiotensin system - a therapeutic target in COVID-19? Clin Med (Lond) 20 e72-115
[8]  
Hughes G(2020)COVID-19 diagnosis and management: a comprehensive review J Intern Med 288 192-589
[9]  
Felsenstein S(2020)Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions Autoimmun Rev 19 102567-290
[10]  
Herbert JA(2020)The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic Mult Scler Relat Disord 43 102174-2201